Scarica l'app Stockscreener
44.23
4.05%
1.72
Pre-mercato:
45.70
1.47
+3.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$42.51
Aprire:
$44.29
Volume 24 ore:
1.54M
Relative Volume:
1.46
Capitalizzazione di mercato:
$3.96B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-7.4461
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
-11.45%
1M Prestazione:
+3.46%
6M Prestazione:
-0.11%
1 anno Prestazione:
+42.45%
Intervallo 1D:
$43.95
$46.03
Intervallo di 1 settimana:
$35.95
$46.03
Portata 52W:
$28.72
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
44.23 | 3.96B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Brevan Howard Capital Management LP Takes $551,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Upgraded at Bank of America - Defense World
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by AQR Capital Management LLC - MarketBeat
PTC Therapeutics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- PTCT - ACCESS Newswire
PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Buy at Bank of America - MarketBeat
William Blair Lifts Earnings Estimates for PTC Therapeutics - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Cubist Systematic Strategies LLC - MarketBeat
PTCT FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Driehaus Capital Management LLC Acquires New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Raised to Strong-Buy at StockNews.com - Defense World
Leerink Partnrs Issues Optimistic Outlook for PTCT Earnings - Defense World
William Blair Boosts Earnings Estimates for PTC Therapeutics - Defense World
JPMorgan Chase & Co. Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $67.00 - Defense World
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Blackstone Inc. - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Upgraded at Citigroup - Defense World
Tudor Investment Corp ET AL Increases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics projects $650M to $800M revenue for 2025 amid global SUFIANCE launch preparations - MSN
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lost Money on PTC Therapeutics, Inc. (PTCT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Shareholders Who Lost Money on PTC Therapeutics, Inc. (PTCT) Should Contact Levi & Korsinsky About Securities Fraud InvestigationPTCT - ACCESS Newswire
B of A Securities Upgrades PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Strong Earnings - MarketBeat
Cantor Fitzgerald Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $112.00 - MarketBeat
BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55 - marketscreener.com
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday - Benzinga
PTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $67.00 at JPMorgan Chase & Co. - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Upgraded by Citigroup - MarketBeat
Baker BROS. Advisors LP Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Receives Upgrade from BofA with New Price Target | PTCT Stock News - GuruFocus
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up on Strong Earnings - Defense World
PTCT: Barclays Lowers Price Target for PTC Therapeutics to $42 | PTCT Stock News - GuruFocus
ATTENTION PTCT SHAREHOLDERS: Investors who lost money on PTC Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
PTC Therapeutics, Inc. (PTCT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call Transcript - Insider Monkey
PTCT: Barclays Reduces Price Target for PTC Therapeutics | PTCT Stock News - GuruFocus
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data - Seeking Alpha
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PTC Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Price T Rowe Associates Inc. MD Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTCT Analyst Raises Price Target Amid Outperform Rating | PTCT S - GuruFocus
PTCT: Baird Adjusts Price Target for PTC Therapeutics | PTCT Stock News - GuruFocus
PTCT Analyst Raises Price Target Amid Outperform Rating | PTCT Stock News - GuruFocus
PTC Therapeutics (NASDAQ:PTCT) Shares Gap DownHere's What Happened - MarketBeat
Earnings call transcript: PTC Therapeutics beats Q1 2025 revenue forecast By Investing.com - Investing.com UK
PTC Therapeutics (PTCT) Target Price Adjusted by Cantor Fitzgerald | PTCT Stock News - GuruFocus
PTC Therapeutics to Participate at Upcoming Investor Conferences - Seeking Alpha
PTC Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by PTC Therapeutics, Inc. (PTCT) - ACCESS Newswire
PTC Therapeutics (PTCT) Price Target Lowered by JP Morgan | PTCT Stock News - GuruFocus
PTC Therapeutics upgraded by Citigroup with a new price target - Quantisnow
Earnings call transcript: PTC Therapeutics beats Q1 2025 revenue forecast - Investing.com Australia
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):